<?xml version='1.0' encoding='utf-8'?>
<document id="29949996"><sentence text="Modeling polypharmacy side effects with graph convolutional networks." /><sentence text="The use of drug combinations, termed polypharmacy, is common to treat patients with complex diseases or co-existing conditions" /><sentence text=" However, a major consequence of polypharmacy is a much higher risk of adverse side effects for the patient" /><sentence text=" Polypharmacy side effects emerge because of drug-drug interactions, in which activity of one drug may change, favorably or unfavorably, if taken with another drug" /><sentence text=" The knowledge of drug interactions is often limited because these complex relationships are rare, and are usually not observed in relatively small clinical testing" /><sentence text=" Discovering polypharmacy side effects thus remains an important challenge with significant implications for patient mortality and morbidity" /><sentence text="" /><sentence text="Here, we present Decagon, an approach for modeling polypharmacy side effects" /><sentence text=" The approach constructs a multimodal graph of protein-protein interactions, drug-protein target interactions and the polypharmacy side effects, which are represented as drug-drug interactions, where each side effect is an edge of a different type" /><sentence text=" Decagon is developed specifically to handle such multimodal graphs with a large number of edge types" /><sentence text=" Our approach develops a new graph convolutional neural network for multirelational link prediction in multimodal networks" /><sentence text=" Unlike approaches limited to predicting simple drug-drug interaction values, Decagon can predict the exact side effect, if any, through which a given drug combination manifests clinically" /><sentence text=" Decagon accurately predicts polypharmacy side effects, outperforming baselines by up to 69%" /><sentence text=" We find that it automatically learns representations of side effects indicative of co-occurrence of polypharmacy in patients" /><sentence text=" Furthermore, Decagon models particularly well polypharmacy side effects that have a strong molecular basis, while on predominantly non-molecular side effects, it achieves good performance because of effective sharing of model parameters across edge types" /><sentence text=" Decagon opens up opportunities to use large pharmacogenomic and patient population data to flag and prioritize polypharmacy side effects for follow-up analysis via formal pharmacological studies" /><sentence text="" /><sentence text="Source code and preprocessed datasets are at: http://snap" /><sentence text="stanford" /><sentence text="edu/decagon" /><sentence text="" /></document>